DE69615843D1 - Il-8 antagonisten zur behandlung von asthma - Google Patents

Il-8 antagonisten zur behandlung von asthma

Info

Publication number
DE69615843D1
DE69615843D1 DE69615843T DE69615843T DE69615843D1 DE 69615843 D1 DE69615843 D1 DE 69615843D1 DE 69615843 T DE69615843 T DE 69615843T DE 69615843 T DE69615843 T DE 69615843T DE 69615843 D1 DE69615843 D1 DE 69615843D1
Authority
DE
Germany
Prior art keywords
antagonists
treating asthma
asthma
treating
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69615843T
Other languages
English (en)
Other versions
DE69615843T2 (de
Inventor
A Hebert
C Kabakoff
W Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DE69615843D1 publication Critical patent/DE69615843D1/de
Application granted granted Critical
Publication of DE69615843T2 publication Critical patent/DE69615843T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69615843T 1995-06-27 1996-06-26 Il-8 antagonisten zur behandlung von asthma Expired - Fee Related DE69615843T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/491,334 US5874080A (en) 1994-03-03 1995-06-27 Anti-IL-8 monoclonal antibodies for treatment of asthma
PCT/US1996/011033 WO1997001354A1 (en) 1995-06-27 1996-06-26 Il-8 antagonists for treatment of inflammatory disorders and asthma

Publications (2)

Publication Number Publication Date
DE69615843D1 true DE69615843D1 (de) 2001-11-15
DE69615843T2 DE69615843T2 (de) 2002-05-16

Family

ID=23951745

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69615843T Expired - Fee Related DE69615843T2 (de) 1995-06-27 1996-06-26 Il-8 antagonisten zur behandlung von asthma

Country Status (12)

Country Link
US (1) US5874080A (de)
EP (1) EP0840620B1 (de)
JP (1) JPH11509840A (de)
AT (1) ATE206621T1 (de)
AU (1) AU727343C (de)
CA (1) CA2222024A1 (de)
DE (1) DE69615843T2 (de)
DK (1) DK0840620T3 (de)
ES (1) ES2165506T3 (de)
NZ (1) NZ311561A (de)
PT (1) PT840620E (de)
WO (1) WO1997001354A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701342B2 (en) * 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
EP0968291B1 (de) 1997-02-21 2004-01-28 Genentech, Inc. Antikörperfragment-polymerkonjugate
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
WO1999065310A1 (en) * 1998-06-17 1999-12-23 Smithkline Beecham Corporation Il-8 receptor antagonists
US20080038274A1 (en) * 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
AU2001292846A1 (en) * 2000-09-20 2002-04-29 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
EP1494711A4 (de) * 2002-03-19 2008-05-28 Abgenix Inc Verfahren zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
BR0315942A (pt) * 2002-11-27 2005-10-04 Dmi Biosciences Inc Tratamento de doenças e condições mediadas pelo aumento de fosforilação
EP1590364B1 (de) * 2002-12-16 2011-10-05 Genmab A/S Humane monoklonale antikörper gegen interleukin 8 (il-8)
CA2605964A1 (en) * 2005-04-20 2006-10-26 Amgen Fremont Inc. High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
PT98072B (pt) * 1990-06-22 1998-11-30 Chiron Corp Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
WO1992006196A1 (en) * 1990-09-28 1992-04-16 Cetus Oncology Corporation Gro genes, proteins, and uses thereof
WO1992006697A1 (en) * 1990-10-23 1992-04-30 Repligen Corporation Anti-inflammatory composition
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
AU2348492A (en) * 1991-07-19 1993-02-23 East Carolina University Method of treating asthma
WO1994004173A1 (en) * 1992-08-21 1994-03-03 The Scripps Research Institute Therapeutic compositions and methods for inhibiting il-8-mediated inflammation
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP0840620A1 (de) 1998-05-13
PT840620E (pt) 2002-04-29
US5874080A (en) 1999-02-23
ES2165506T3 (es) 2002-03-16
ATE206621T1 (de) 2001-10-15
CA2222024A1 (en) 1997-01-16
JPH11509840A (ja) 1999-08-31
AU727343B2 (en) 2000-12-14
DE69615843T2 (de) 2002-05-16
AU6292496A (en) 1997-01-30
NZ311561A (en) 1999-10-28
EP0840620B1 (de) 2001-10-10
DK0840620T3 (da) 2002-02-04
WO1997001354A1 (en) 1997-01-16
AU727343C (en) 2002-01-03

Similar Documents

Publication Publication Date Title
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
DE69703649T2 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DK0724456T3 (da) CD40-Antistoffer
DE60043957D1 (de) Verfahren zur Behandlung von Entzündungen
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
MX9800760A (es) Metodos para el tratamiento del asma alergica.
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
DE69116921T2 (de) Verfahren zur Reinigung von monoklonalen Antikörpern
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
EA199700196A1 (ru) Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом
DE59611293D1 (de) Protein mit dnase-aktivität
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee